---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-057216"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:32:22.704144+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco Q1 revenue $1.225B, adj. EPS $0.36; FY22 guidance lowered on FX headwind of $140M

## Summary
- Q1 revenue $1,225M (-1% reported, +2% CER); reported net income $48M vs -$61M; adjusted EPS $0.36 vs $0.37.
- FY22 revenue guidance cut to $4,700-4,755M from $4,745-4,800M due to incremental $45M FX headwind; adj. EPS guidance $1.15-1.21.
- Strategic alliance with Royal DSM for exclusive U.S. rights to Bovaer methane-reducing feed additive; >$200M annual revenue potential.
- Pet Health revenue $639M; Seresto grew 6% to $161M; Advantage declined 5% to $137M, with temporary U.S. stock-outs.
- Completed $406M tender on 4.272% Senior Notes due 2023; new $250M term facility with Farm Credit; net leverage 5.6x.

## SEC filing metadata
- accession: 0001104659-22-057216
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465922057216/0001104659-22-057216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465922057216/tm2214854d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-057216
- JSON: https://secwatch.observer/filing/0001104659-22-057216.json
- Plain text: https://secwatch.observer/filing/0001104659-22-057216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.